NCT01157156View on ClinicalTrials.gov

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

September 30, 2001

Study Completion Date

September 30, 2001

Conditions

Peripheral Arterial Occlusive Disease

Interventions

DRUG

XRP0038 (NV1FGF)

"Pharmaceutical form:solution~Route of administration: intramuscular"

Trial Locations (2)

Unknown

Minneapolis

Tempere

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY